Version 1
: Received: 5 May 2022 / Approved: 6 May 2022 / Online: 6 May 2022 (09:14:17 CEST)
How to cite:
Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints.org2022, 2022050068. https://doi.org/10.20944/preprints202205.0068.v1.
Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints.org 2022, 2022050068. https://doi.org/10.20944/preprints202205.0068.v1.
Cite as:
Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints.org2022, 2022050068. https://doi.org/10.20944/preprints202205.0068.v1.
Avallone, A.; Bimonte, S.; Cardone, C.; Forte, C.A.; Cascella, M.; Cuomo, A. Mechanisms and Therapeutic Perspectives of Chemotherapy-Induced Peripheral Neuropathy: An Update. Preprints.org 2022, 2022050068. https://doi.org/10.20944/preprints202205.0068.v1.
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) develops as a challenging nerve-damaging adverse effect of anticancer drugs used in chemotherapy. The disorder may require a dose reduction of chemo-therapy and its most common sensory symptoms are severe pain, tingling, and numbness in the hands and feet. CIPN affects dramatically the patient's quality of life (QoL). Pain and sensory abnormalities may occur for months, or even years after the termination of chemotherapy. This disease has complicated pathophysiology featured by underlying mechanisms not completely known. Although many pharmaco-logical and non-pharmacological therapeutic approaches have been tested to overcome these symptoms, there is currently no standardized cure to prevent or treat CIPN. According to current guidelines, Duloxe-tine is the only recommended agent for painful neuropathic symptoms. Therefore, finding effective thera-pies for CIPN is mandatory. The purpose of this review is to dissect CIPN, the target and immunothera-py-based approaches to this disorder, as well as to offer new insights for novel therapeutic perspectives.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.